← Eichor
Condition: Brca1 2 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Brca1 2

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ov
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT07532434Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2 · 3 location(s) · Okayama University · NCT05485766Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05769517Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NA · 1 location(s) · CHU de Quebec-Universite Laval · NCT06817694Study of How People Make Decisions About Prostate Cancer Risk
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT07197723Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT07039552Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06775470Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest f
Phase N/A · 2 location(s) · Centre Georges Francois Leclerc · NCT06111417Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204Pancreatic Cancer Screening for At-risk Individuals
Phase N/A · 1 location(s) · Beth Israel Deaconess Medical Center · NCT05006131Men at High Genetic Risk for Prostate Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT03805919PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06533384Pancreatic Cancer Genetics
Phase N/A · 1 location(s) · Columbia University · NCT01102569Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314Identifying and Caring for Individuals With Inherited Cancer Syndrome
NA · 2 location(s) · OHSU Knight Cancer Institute · NCT04494945Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Phase N/A · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT02478892A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NA · 549 location(s) · NRG Oncology · NCT04251052Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT03396341Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Phase 3 · 1 location(s) · Fudan University · NCT04520074Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 · 8 location(s) · Senhwa Biosciences, Inc. · NCT04890613A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NA · 1 location(s) · Vasileios Kalles · NCT07292246Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+
Phase 2 · 36 location(s) · GBG Forschungs GmbH · NCT06201234CfDNA in Hereditary And High-risk Malignancies 2
Phase N/A · 8 location(s) · University Health Network, Toronto · NCT06726642A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
Phase 1 · 8 location(s) · FoRx Therapeutics AG · NCT07356453The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Brea
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT06488378Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-P
Phase 3 · 301 location(s) · AstraZeneca · NCT06380751Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene M
Phase 2 · 133 location(s) · SWOG Cancer Research Network · NCT05806515
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.